|
186 Products |
| 186 Products |
|
1696 Diseases |  |
95004 News |  |
| «12...149150151152153154155156157158159...10651066» |
- | bleomycin / Generic mfg.
Retrospective data, Journal: The combined application of bleomycin and triamcinolone for the treatment of keloids and hypertrophic scars: An effective therapy for treating refractory keloids and hypertrophic scars. (Pubmed Central) - Jun 30, 2023
The combined application of bleomycin and triamcin acetonide can effectively cure keloids and hypertrophic scars.
- || dexamethasone / Generic mfg., dapsone / Generic mfg., aspirin / Generic mfg.
Review, Journal, IO biomarker: Treatment mechanism of immune triad from the repurposing drug against COVID-19. (Pubmed Central) - Jun 30, 2023
They are shown to work harmoniously with modulating ILCs. Therefore, it needs to prescribe this immune triad to alleviate the clinical pathologic course and block exacerbation mechanisms due to diverse SARS-CoV-2 variants.
- | methylprednisolone acetate / Generic mfg.
Journal: Clinical and Biochemical Correlation of Intra-articular Platelet-Rich Plasma and Corticosteroid Using Serum Matrix Metalloproteinase 3 (MMP-3) Levels in Osteoarthritis of Knee. (Pubmed Central) - Jun 30, 2023
Accordingly, patients in the PRP group were injected with freshly prepared PRP (3 ml) within two hours of preparation, whereas those in the CS received 80 mg of methylprednisolone acetate...We could not find any significant change in levels of MMP3 post PRP and CS injections, which signifies that these two modalities do not have any effect in either preventing cartilage degeneration or promoting cartilage regeneration. Our findings have shown that PRP injections are safe, minimally invasive, and effective treatment modalities for OA knee.
- | dexamethasone / Generic mfg.
Journal: Negative consequences of reduced protein diets supplemented with synthetic amino acids for performance, intestinal barrier function, and caecal microbiota composition of broiler chickens. (Pubmed Central) - Jun 30, 2023
Half of the birds in each dietary treatment were challenged by dexamethasone (DEX) to induce a leaky gut...At the family level, Bifidobacteriaceae, Unclassified Bifidobacteriales, Enterococcaceae, Enterobacteriaceae, and Lachnospiraceae were the main taxa in birds fed 15.6% protein. Despite supplementation of synthetic amino acids, severe reduction of dietary protein compromised performance and intestinal health parameters in broilers, evidenced by differential mRNA expression of tight junction proteins, higher permeability, and changes in caecal microbiota composition.
- || dexamethasone / Generic mfg.
PK/PD data, Journal: Anti-Inflammatory Effects of Dexamethasone in COVID-19 Patients: Translational Population PK/PD Modeling and Simulation. (Pubmed Central) - Jun 30, 2023
Possibly beneficial is DEX given at a dose of 12 mg compared to 6 mg. The popPK/PD model may be useful in the assessment of other anti-inflammatory compounds as well as drug combinations in the treatment of cytokine storms.
- || hydrocortisone / Generic mfg.
Dex Methylpred(Soludedrol) Pred Hydrocortisone: Don't Stop Pred Hastily! (Twitter) - Jun 29, 2023
- | fluocinolone acetonide / Generic mfg.
Journal: Functional and Morphological Responses to Fluocinolone Acetonide 0.19?mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve. (Pubmed Central) - Jun 29, 2023
Overall, improvement of BCVA and CMT after FAc injection was maintained over 24 months. This study is registered in the German Clinical Trials Register under the DRKS-ID: DRKS00024399.
- | methylprednisolone acetate / Generic mfg.
Journal: Transforaminal Injections of Platelet-Rich Plasma Compared with Steroid in Lumbar radiculopathy: A Prospective, Double-Blind Randomized Study. (Pubmed Central) - Jun 29, 2023
60 patients were randomized to be treated with single transforaminal injection of PRP (n?=?29) or steroid (methylprednisolone acetate [n?=?31])...No serious complications were seen. Transforaminal injections of PRP and steroid improve short-term (up to 3
- | dexamethasone / Generic mfg.
Journal: Impact of dexamethasone dose on return visits at a pediatric emergency department. (Pubmed Central) - Jun 29, 2023
Transforaminal injections of PRP and steroid improve short-term (up to 3 No abstract available
- | hydroxychloroquine / Generic mfg., budesonide / Generic mfg.
Journal: Novel agents for treating IgA nephropathy. (Pubmed Central) - Jun 29, 2023
No abstract available In recent years, IgAN has become the focus of a considerable number of clinical studies that will significantly advance the development of new therapy strategies.
- || Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
Review, Journal, CINV: The clinical research study for fosaprepitant to prevent chemotherapy-induced nausea and vomiting: A review. (Pubmed Central) - Jun 29, 2023
The dimeglumine salt form of fosaprepitant can be utilized as an intravenous injectable drug, which surpasses aprepitant's oral admistration limits...In general, fosaprepitant is worthy of clinical promotion and has a large market potential. This article reviews the clinical studies on fosaprepitant conducted in recent years, with the aim of providing a basis for the rational clinical selection of antiemetic drugs.
- || Rybrevant (amivantamab-vmjw) / J&J
Trial primary completion date: SKIPPirr: Premedication to Reduce Amivantamab Associated Infusion Related Reactions (clinicaltrials.gov) - Jun 29, 2023
P2, N=120, Recruiting, Sponsor: Janssen Research & Development, LLC
This article reviews the clinical studies on fosaprepitant conducted in recent years, with the aim of providing a basis for the rational clinical selection of antiemetic drugs. Trial primary completion date: Jun 2024 --> Dec 2024
- || mezigdomide (CC-92480) / BMS
Trial primary completion date, Combination therapy: CC-92480-MM-002: A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov) - Jun 29, 2023
P1/2, N=424, Recruiting, Sponsor: Celgene
Trial primary completion date: Jun 2024 --> Dec 2024 Trial primary completion date: Jan 2025 --> Nov 2023
- ||| Aliqopa (copanlisib) / Bayer, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial termination, Combination therapy: Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma (clinicaltrials.gov) - Jun 29, 2023
P1, N=12, Terminated, Sponsor: University of Washington
Trial primary completion date: Jan 2025 --> Nov 2023 Active, not recruiting --> Terminated; Terminated due to low accrual
- ||| Tecvayli (teclistamab-cqyv) / Genmab, J&J
Trial completion date, Monotherapy: MajesTEC-9: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 29, 2023
P3, N=590, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Terminated; Terminated due to low accrual Trial completion date: Aug 2031 --> May 2032
- | Trial completion date, Trial primary completion date: Real MM: STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (clinicaltrials.gov) - Jun 29, 2023
P4, N=450, Recruiting, Sponsor: University of Turin, Italy
Trial completion date: Aug 2031 --> May 2032 Trial completion date: Jan 2025 --> Jan 2030 | Trial primary completion date: Jan 2023 --> Jan 2024
- | Enbrel (etanercept) / Pfizer, Amgen, Yisaipu (etanercept biosimilar) / Cipla, 3SBio, Abbott
New trial: Recombinant Human Tumor Necrosis Factor-? Receptor ? Fusion Protein in the Treatment of Acute Gout (clinicaltrials.gov) - Jun 29, 2023
P=N/A, N=100, Not yet recruiting, Sponsor: Lihua Duan
- ||| Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
Enrollment open: CHOROS ORION: Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol) (clinicaltrials.gov) - Jun 29, 2023
P=N/A, N=250, Recruiting, Sponsor: AstraZeneca
Trial completion date: Jan 2025 --> Jan 2030 | Trial primary completion date: Jan 2023 --> Jan 2024 Not yet recruiting --> Recruiting
- ||||| Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed: REGENCY: A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (clinicaltrials.gov) - Jun 29, 2023
P3, N=252, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Darzalex (daratumumab) / J&J
Enrollment closed, Trial completion date, Trial primary completion date, Minimal residual disease: Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy (clinicaltrials.gov) - Jun 29, 2023
P2, N=57, Active, not recruiting, Sponsor: University of Michigan Rogel Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Oct 2026 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2023
- | hydrocortisone / Generic mfg.
Journal: Alternatives to Hydrocortisone for Hemodynamic Support in Septic Shock Management Due to Medication Shortage. (Pubmed Central) - Jun 28, 2023
Methylprednisolone and dexamethasone are considered therapeutic alternatives to hydrocortisone. This commentary aims to guide clinicians on the alternative to hydrocortisone among septic shock patients due to medication shortage.
- | dexamethasone / Generic mfg.
Journal, Cytokine release syndrome: Dissecting the mechanisms underlying the Cytokine Release Syndrome (CRS) mediated by T Cell Bispecific Antibodies. (Pubmed Central) - Jun 28, 2023
This commentary aims to guide clinicians on the alternative to hydrocortisone among septic shock patients due to medication shortage. Our work sheds a new light on the cellular and molecular players involved in cytokine release driven by TCBs and provides rationale for the prevention of CRS in patients treated with TCBs.
- | dexamethasone / Generic mfg.
Preclinical, Journal: Micro Injection Molding of Drug-Loaded Round Window Niche Implants for an Animal Model Using 3D-Printed Molds. (Pubmed Central) - Jun 28, 2023
Our work sheds a new light on the cellular and molecular players involved in cytokine release driven by TCBs and provides rationale for the prevention of CRS in patients treated with TCBs. In this study, drug-loaded (10 wt% Dexamethasone) guinea pig round window niche implants (GP-RNIs, ~1.30 mm
- | dexamethasone / Generic mfg.
Journal: Transscleral Delivery of Dexamethasone-Loaded Microparticles Using a Dissolving Microneedle Array. (Pubmed Central) - Jun 28, 2023
Additionally, images of the sectioned sclera confirmed the diffusion of fluorescent-labelled microparticles within the scleral matrix. The system therefore represents a potential approach for minimally invasive Dex delivery to the posterior of the eye, which lends itself to self-administration and hence high patient convenience.
- ||| dexamethasone / Generic mfg., prednisone / Generic mfg.
Clinical: 1. Would you say that to her parents, or the parents of other kids it killed? https://t.co/bnfZQSSL09 2. Aside from how prednisone doesn't seem very effective compared to dexamethasone, how does that explain the death rate being multiple times higher for unvaccinated people? (Twitter) - Jun 28, 2023
- || Biomarker, Review, Journal: Pharmacogenetic Testing for the Pediatric Gastroenterologist: Actionable Drug-Gene Pairs to Know. (Pubmed Central) - Jun 28, 2023
Our goal is to provide a practical tutorial on the currently available pharmacogenetic testing options and a results interpretation for drug-gene pairs important to medications commonly used in pediatric gastroenterology. We focus on evidence-based clinical guidelines published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) to highlight relevant drug-gene pairs, including proton pump inhibitors and selective serotonin reuptake inhibitors and cytochrome P450 (CYP) 2C19, ondansetron and CYP2D6, 6-mercaptopurine and TMPT and Nudix hydrolase 15 (NUDT15), and budesonide and tacrolimus and CYP3A5.
- | Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal, Immunomodulating: The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity. (Pubmed Central) - Jun 28, 2023
Eltrombopag and Romiplostim are safer and more effective than Prednisolone, HD-DXM, and Rituximab. They might be reasonable beneficial options after a one-month HD-DXM regimen.
- | remdesivir / Generic mfg., dexamethasone / Generic mfg.
Journal: Treatment of COVID-19 during the Acute Phase in Hospitalized Patients Decreases Post-Acute Sequelae of COVID-19. (Pubmed Central) - Jun 28, 2023
Treatment with dexamethasone and/or remdesivir may be useful to reduce the impact of PASC secondary to SARS-CoV-2 infection. In addition, we identified female gender, obesity, asthma, and disease severity as risk factors for having PASC.
- | dexamethasone injection / Generic mfg.
Journal, Real-world evidence, Real-world: Visual and Anatomical Outcomes of a Single Intravitreal Dexamethasone in Diabetic Macular Edema: An 8 Year Real-World Study. (Pubmed Central) - Jun 28, 2023
Real-world re-treatment was observed to be delayed until after visual benefits were lost in half of the cohort. Further research will be needed to study the effects of delays in re-treatment.
- | dexamethasone / Generic mfg.
Preclinical, Journal: Phaeanthus vietnamensis Ban Ameliorates Lower Airway Inflammation in Experimental Asthmatic Mouse Model via Nrf2/HO-1 and MAPK Signaling Pathway. (Pubmed Central) - Jun 28, 2023
Mice were orally administered various doses of PVE once daily (50, 100, 200 mg/kg) or dexamethasone (Dex; 2.5 mg/kg) or Saline 1 h before the OVA challenge...Moreover, the PVE treatment group significantly increased the expressions of antioxidant enzymes Nrf2 and HO-1 in the lung tissue and the level of those antioxidant enzymes in the BALF, decreasing the oxidative stress marker MDA level in the BALF, leading to the relieving the activation of MAPK signaling in asthmatic condition. The present study demonstrated that Phaeanthus vietnamensis B
- | dexamethasone / Generic mfg., dexmedetomidine / Generic mfg.
Trial completion date, Trial primary completion date: Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block (clinicaltrials.gov) - Jun 28, 2023
P4, N=60, Recruiting, Sponsor: Damanhour Teaching Hospital
The present study demonstrated that Phaeanthus vietnamensis B Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Apr 2023 --> Aug 2023
- | triamcinolone acetonide / Generic mfg.
Trial completion date, Trial primary completion date, Surgery, Compliance: Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population (clinicaltrials.gov) - Jun 28, 2023
P4, N=70, Recruiting, Sponsor: University of California, San Francisco
Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Apr 2023 --> Aug 2023 Trial completion date: Mar 2023 --> Jun 2024 | Trial primary completion date: Mar 2023 --> Jun 2024
- | dexamethasone injection / Generic mfg.
Trial completion date: Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) (clinicaltrials.gov) - Jun 28, 2023
P3, N=520, Active, not recruiting, Sponsor: Oxford University Clinical Research Unit, Vietnam
Trial completion date: Mar 2023 --> Jun 2024 | Trial primary completion date: Mar 2023 --> Jun 2024 Trial completion date: Jun 2023 --> Jun 2024
- | oxaliplatin / Generic mfg.
New P2 trial: Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors (clinicaltrials.gov) - Jun 28, 2023
P2, N=500, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- || Sarclisa (isatuximab-irfc) / Sanofi, Blenrep (belantamab mafodotin-blmf) / GSK
New P2 trial: ISABELA: Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 28, 2023
P2, N=50, Not yet recruiting, Sponsor: Massachusetts General Hospital
- ||||||| Melflufen (melphalan flufenamide) / Oncopeptides
Trial completion, Trial completion date: OCEAN: A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (clinicaltrials.gov) - Jun 28, 2023
P3, N=495, Completed, Sponsor: Oncopeptides AB
Trial completion date: Jun 2023 --> Jun 2024 Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Feb 2023
- | dexamethasone / Generic mfg.
Journal: Dexamethasone Modulates the Dynamics of Wnt Signaling in Human Trabecular Meshwork Cells. (Pubmed Central) - Jun 27, 2023
We observed a sequential pattern of peak expression between AXIN2, sFRP1, and MYOC. Based on the study, we propose that sFRP1 upregulation could be a result of a negative feedback mechanism generated by stressed TM cells to suppress abnormal Wnt signaling activities.
- | dexamethasone / Generic mfg.
Journal: Conceptualization and Investigation of Multicomponent Polymer Networks as Prospective Corticosteroid Carriers. (Pubmed Central) - Jun 27, 2023
Based on the study, we propose that sFRP1 upregulation could be a result of a negative feedback mechanism generated by stressed TM cells to suppress abnormal Wnt signaling activities. Dexamethasone (DXM) is a highly potent and long-acting synthetic glucocorticoid with anti-inflammatory, anti-allergic, and immunosuppressive effects...In vitro DSP release was studied in buffer solution (BS) with pH 7.4 at 37
- || Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
Review, Journal: Post-COVID-19 Anosmia and Therapies: Stay Tuned for New Drugs to Sniff Out. (Pubmed Central) - Jun 27, 2023
The other interesting drugs are 13-cis-retinoic acid plus aerosolized Vitamin D, dexamethasone, and corticosteroid nasal irrigation...Some of these therapies are very promising and are almost at the end of experimentation. They also provide hope in this field, which not addressed until recently.
- | triamcinolone acetonide topical / Generic mfg.
Journal: A "Nonallergen" Strikes Back: Allergic Contact Dermatitis to Parabens in Triamcinolone Ointment. (Pubmed Central) - Jun 27, 2023
They also provide hope in this field, which not addressed until recently. No abstract available
- || budesonide / Generic mfg.
Review, Journal: IgA Nephropathy: Current Treatment and New Insights. (Pubmed Central) - Jun 27, 2023
A better understanding of the pathophysiology of IgAN in recent years has led to the development of several new therapeutic agents. In this review, we summarize the current therapeutic approach for patients with IgAN as well as all novel investigational agents.
- |||| dexamethasone / Generic mfg.
Clinical, Immunomodulating: New publication: The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer https://t.co/4zWb8n73Zf Kai CC Johnson, @quirogad @DrPKSudi @DrGattiMays @Nicole_O_W @StoverLab @sardesai_sagar, Mathew Cherian et al. (Twitter) - Jun 27, 2023
- ||||| Sarclisa (isatuximab-irfc) / Sanofi
Trial termination, Combination therapy: ISAKIDS: Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 27, 2023
P2, N=67, Terminated, Sponsor: Sanofi
In this review, we summarize the current therapeutic approach for patients with IgAN as well as all novel investigational agents. Active, not recruiting --> Terminated; Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns.
- | methylprednisolone sodium succinate / Generic mfg.
Trial completion date, Trial primary completion date: Efficacy of Nerve Blocks for Episodic Migraine (clinicaltrials.gov) - Jun 27, 2023
P2, N=60, Not yet recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Terminated; Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns. Trial completion date: Sep 2023 --> Jun 2024 | Trial primary completion date: Sep 2023 --> Dec 2023
- || Elrexfio (elranatamab-bcmm) / Pfizer, maplirpacept (TTI-622) / Pfizer
Enrollment change, Combination therapy: MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 27, 2023
P1b, N=14, Recruiting, Sponsor: Pfizer
Trial completion date: Sep 2023 --> Jun 2024 | Trial primary completion date: Sep 2023 --> Dec 2023 N=56 --> 14
- | Metopirone (metyrapone) / HRA Pharma
New P1 trial: The Role of Glucocorticoids to Maintain Energy Homeostasis During Starvation (Gluco-Starve) (clinicaltrials.gov) - Jun 27, 2023
P1, N=20, Recruiting, Sponsor: Eleonora Seelig
- | dexamethasone / Generic mfg., ibuprofen / Generic mfg.
Enrollment open: Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain. (clinicaltrials.gov) - Jun 27, 2023
P4, N=132, Recruiting, Sponsor: Montefiore Medical Center
N=56 --> 14 Not yet recruiting --> Recruiting
- | dexamethasone / Generic mfg.
Journal: Drug-Eluting Sandwich Hydrogel Lenses Based on Microchamber Film Drug Encapsulation. (Pubmed Central) - Jun 26, 2023
The developed delivery system showed sustained and controlled release of the drug. The central visual part of the lenses was cleared from the polylactic acid microchamber in order to maintain a clean central aperture similar to the cosmetic-colored hydrogel contact lenses.
- | remdesivir / Generic mfg., hydroxychloroquine / Generic mfg., dexamethasone / Generic mfg.
Journal: Drug discovery through Covid-19 genome sequencing with siamese graph convolutional neural network. (Pubmed Central) - Jun 26, 2023
Other methods obtained hydroxychloroquine as an effective drug which was rejected by WHO. However, The experimental results show that Remdesivir and Dexamethasone are the most effective drugs, with 97.41 and 97.93%, respectively.
- | dexamethasone / Generic mfg.
Preclinical, Journal: Qing-Kai-Ling oral liquid alleviated pneumonia via regulation of intestinal flora and metabolites in rats. (Pubmed Central) - Jun 26, 2023
Furthermore, QKL was effective in alleviating pneumonia and provided protection equivalent to that of the positive drug dexamethasone...Our findings indicated that QKL could potentially modulate intestinal flora dysbiosis, improve host-microbiota co-metabolism dysregulation and regulate gene expression in the lungs, thereby mitigating LPS-induced pneumonia in rats. The study may provide new ideas for the clinical application and further development of QKL.